News

Morningstar18d
OSE Immunotherapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update
NANTES, France – March 26, 2025, 6:15 p.m. CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a biotech company dedicated to developing first-in-class therapies in immuno-oncology ...
Morningstar5d
OSE Immunotherapeutics to Present Groundbreaking Extension Period Data on Lusvertikimab at DDW 2025
New Clinical Data from Phase 2 Extension Period in Ulcerative Colitis on Long-Term Benefits and Safety of Anti-IL-7R mAb Lusvertikimab NANTES, France – April 9, 2025, 7:30 a.m. CET - OSE ...
WDTN1mon
OSE Immunotherapeutics Reports Full Phase 2 Induction Results for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the 20th Congress of ECCO
NANTES, France – February 24, 2025, 7:30am CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), presented full efficacy and safety data from the induction period of the randomized ...
ADVFN1mon
OSE Immunotherapeutics Reports Full Phase 2 Induction Results for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the 20th Congress of ECCO
OSE Immunotherapeutics Reports Full Phase 2 Induction Results for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the 20th Congress of ECCO NANTES, France – February 24, 2025, 7:30am CET ...